New G protein inhibitor identified, with potential for cancer therapies
RI-MUHC team publishes study in Nature Communications describing a novel molecule that inhibits growth of cancer cells
RI-MUHC team identifies potential diagnostic biomarker for pancreatic cancer
Study demonstrates that regenerative protein 3A/3B promotes a newly recognized precursor of pancreatic...
How does the hunger-suppressing hormone leptin cross the blood-brain barrier?
Specialized cells called pericytes play a key role, reveals new work from researchers at the RI-MUHC
RI-MUHC study explores how to overcome the resistance of bladder tumours to radiation therapy
Work published in Nature Communications demonstrates a...
RI-MUHC-led team receives $3.4M for new Centre for Applied Nanomedicine
The study of exosomes will foster research on the frontier of personalized medicine
RI-MUHC veterinarians engage in global effort to understand SARS-Cov-2
ARD platform members take centre stage at the 2020 Quebec Veterinary Congress
Paving the way for COVID-19 research
RI-MUHC and McGill Containment level 3 Labs receive $1M in funding to accelerate research with live SARS Cov-2
Containment Level 3 facilities advance COVID-19 research at the RI-MUHC and McGill
Infrastructure to study COVID-19 in a secure environment is creating new possibilities for collaboration and discovery
The RI-MUHC receives and tests the first UV-Disinfection robot in Canada
Novel robotics technology could potentially reduce healthcare-associated infections
Jean-François Trempe appointed Director of the Proteomics Platform, RI-MUHC
The new mandate is effective February 1, 2020